Early trial tests new drug for stubborn lymphoma
NCT ID NCT03985189
Summary
This study tested a new drug called ME-401 in a small group of Japanese patients with a slow-growing type of blood cancer (lymphoma) that had returned or stopped responding to other treatments. The main goal was to check the drug's safety, how the body processes it, and see if it showed any early signs of helping to control the cancer. It was an early-stage trial focused on gathering initial information.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aomori Prefectural Central Hospital
Aomori, 030-8553, Japan
-
Hokkaido University Hospital
Sapporo, Hokkaido, 060-0814, Japan
-
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
Nagoya, Aichi-ken, 466-8650, Japan
-
Kyushu University Hospital
Fukuoka, 812-8582, Japan
-
National Cancer Center Hospital
Chuo-ku, Tokyo, 104-0045, Japan
-
National Hospital Organization Nagoya Medical Center
Nagoya, Aichi-ken, 460-0001, Japan
-
Okayama University Hospital
Okayama, 700-8558, Japan
-
The Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, 135-8550, Japan
-
Tokyo Metropolitan Komagome Hospital
Bunkyo-ku, Tokyo, 113-8677, Japan
Conditions
Explore the condition pages connected to this study.